Admira (Adalimumab) Injection

Description

Description

This page contains brief details about the drug adalimumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Adalimumab is a monoclonal antibody (protein which attaches to a specific target) which was approved for its medical use on 31st December 2002.

Mechanism of Action of Adalimumab

Adalimumab Injection is a biological agent that acts as targeted drug therapy to treat various inflammatory conditions. Adalimumab specifically targets and binds to the tnf Alpha. tnf Alpha a protein that is present in high concentrations in inflammatory diseases. adalimumab blocks the interaction of this protein with its receptors and eventually lower the inflammation.

Uses of Adalimumab

Adalimumab Injection has been developed to treat various inflammatory conditions like rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, ankylosing spondylitis, axial spondylarthritis without evidence of ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis and non-infective uveitis.

Adalimumab Dosage available

For adults with rheumatoid arthritis, psoriatic arthritis and ankylosing Spondylitis, the recommended dose is 40mg every other week. for children with Arthritis of unknown origin, the recommended dose is 10mg every other week for body weight less than 15 kg, 20mg every other week for body weight less than 30kg and 40mg every other week for body weight above 30kg.

For adults with inflammatory bowel disease like crohn’s disease and ulcerative colitis, the recommended dose is 160 MG on day 1, 80mg on 15th day and 40mg every other week starting on day 29. for children body weight less than 40 kg, the recommended dose is 80mg on first day, 40mg on day 15 and 20mg every other week starting on 29th day.

In case of plaque psoriasis and adult uveitis, initial dose is 80 mg followed by 40 mg every other week after initial dose. adalimumab is available as single dose prefilled pen (80mg/0.8ml, 40mg/0.8ml, 40mg/0.4ml) single dose prefilled glass syringe (80mg/0.8ml, 40mg/0.8ml, 40mg/0.4ml, 20mg/0.4ml, 20mg/0.2ml, 10mg/0.2ml, 10mg/0.1ml) and single dose glass vial (40mg/0.8ml).